Common-Size Income Statement
Paying users area
Try for free
Amgen Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get 1-month access to Amgen Inc. for $24.99, or
get full access to the entire website for at least 3 months from $62.19.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Income statement item | Description | The company |
---|---|---|
Operating income | The net result for the period of deducting operating expenses from operating revenues. | Amgen Inc. operating income as a percentage of product sales increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Amgen Inc. income before income taxes as a percentage of product sales increased from 2021 to 2022 but then slightly decreased from 2022 to 2023. |
Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Amgen Inc. net income as a percentage of product sales increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level. |